Stellest, MiSight, Ortho-K or Low-Dose Atropine? A Cincinnati Parent’s Guide to Myopia Management

When a child’s nearsighted prescription keeps increasing, ordinary glasses can restore clear distance vision—but they usually do not address the pattern of continued eye growth. Myopia management uses specific optical or medication strategies to try to slow progression.

At See Well Eyecare, the main options include Essilor Stellest spectacle lenses, MiSight 1 day contact lenses, orthokeratology/CRT lenses and low-dose atropine. They are not interchangeable products, and no option guarantees that progression will stop.

This myopia-management options guide for Cincinnati families explains the practical differences so parents know what to discuss during an evaluation.

Begin With Measurement, Not a Favorite Product

Dr. Baik reviews the child’s prescription history, age at onset, family history, binocular vision, eye health, daily activities and ability to follow a treatment routine. See Well’s parent guide to childhood myopia also explains axial length—the front-to-back measurement of the eye—which may help monitor growth over time.

The American Association for Pediatric Ophthalmology and Strabismus describes specialized glasses, contact lenses, orthokeratology and low-dose atropine among current approaches. The right choice depends on candidacy and consistent use.

Stellest: Myopia-Management Spectacle Lenses

Stellest looks and functions like a pair of glasses. A clear central zone corrects vision while surrounding lenslets create a myopic-defocus signal intended to slow progression.

The FDA authorization applies to children with non-diseased eyes who, when treatment starts, are ages 6–12 with spherical-equivalent myopia from −0.75 D to −4.50 D and astigmatism up to 1.50 D. The exact indication appears in the FDA Stellest review.

Stellest may appeal to families who prefer glasses and want to avoid contact-lens handling. Success still depends on full-time wear, an accurate prescription, proper frame fit and follow-up. See Well’s Stellest lens page explains our dispensing and monitoring process.

MiSight 1 Day: A Daily Disposable Soft Contact Lens

MiSight 1 day is a dual-focus daily disposable contact lens. The FDA indication covers initiation at ages 8–12 for children with non-diseased eyes, spherical-equivalent myopia from −0.75 D to −4.00 D and no more than 0.75 D of astigmatism. The lens is discarded after each removal; review the FDA-approved MiSight labeling.

MiSight may suit a child who is motivated to insert and remove lenses, values freedom from glasses during daytime activities and can follow hygiene rules. It still requires a contact-lens fitting, training and corneal-health monitoring. Learn more on See Well’s MiSight page.

Ortho-K and CRT: Overnight Corneal Reshaping

Orthokeratology uses specially designed rigid lenses during sleep to temporarily reshape the cornea. The child removes the lenses after waking and may see clearly through the day without glasses or daytime contacts.

FDA-authorized orthokeratology devices are indicated for temporary reduction of myopia; using the modality specifically to slow childhood myopia progression is an off-label clinical use in the United States. The FDA’s orthokeratology patient information explains temporary corneal reshaping and the need for professional fitting.

Ortho-K requires careful overnight-lens hygiene, regular follow-up and corneal topography. It may be attractive for active children, but not every prescription, cornea or household routine is a good match. See Well uses Topcon MYAH corneal mapping and offers CRT and Ortho-K care.

Low-Dose Atropine: Prescription Eye Drops

Low-dose atropine is used off-label in the United States for myopia management. “Off-label” means the FDA has not approved that specific drug concentration and indication, not that a clinician is prohibited from prescribing it.

Evidence varies by concentration and population. The LAMP trial compared 0.05%, 0.025% and 0.01% atropine, while a U.S. randomized trial found that 0.01% did not outperform placebo for its primary outcomes. In 2026, AAPOS noted that a proprietary low-dose atropine formulation remained under FDA review in its Myopia Task Force statement.

That is why See Well does not treat “low dose” as a single universal answer. Concentration, pharmacy source, light sensitivity, near blur, adherence and monitoring all deserve discussion.

Can Treatments Be Combined?

Combination treatment may be considered for selected children, especially when progression continues, but more treatment is not automatically better. The added routine, cost, side effects and evidence for a particular combination must be weighed individually.

We track response rather than promising a percentage reduction for every child. A plan may be changed if the prescription or axial length continues to progress, the child struggles with adherence or the ocular surface becomes unhealthy.

Outdoor Time Still Matters

Outdoor time is a healthy supportive habit and appears particularly relevant to reducing the onset of myopia. It does not replace prescribed treatment for a child whose myopia is already progressing. Balanced near-work breaks, comfortable working distance, adequate light and time outdoors can be discussed alongside the clinical plan.

Explore Hyde Park & Nearby Neighborhoods

See Well Eyecare provides myopia-management evaluations in Hyde Park (45208), convenient to Oakley (45209), Mariemont (45227) and Mount Lookout. Families receive one coordinated plan for examination, measurements, product fitting and follow-up.

Local Events & Attractions | Make Outdoor Time Enjoyable

Families visiting the Cincinnati Zoo’s HallZOOween on October 10–11 can turn outdoor time into a shared fall activity. Sunglasses and a hat remain useful in bright conditions, including for children using atropine who notice light sensitivity.

Frequently Asked Questions

Which treatment works best?

There is no single best option for every child. Eligibility, prescription, astigmatism, eye health, progression rate, maturity and family routine all matter.

Are Stellest and MiSight FDA authorized for myopia control?

Yes, within their labeled starting ages, prescription ranges and eye-health criteria. Ortho-K is FDA authorized for temporary myopia reduction, while its use for progression control is off-label. Low-dose atropine for myopia remains off-label.

Will my child still need glasses?

Stellest is itself the child’s glasses. MiSight wearers need backup glasses. Ortho-K wearers may need backup correction, and atropine does not correct distance blur by itself.

How often is follow-up needed?

The schedule depends on treatment and findings. Contact-lens approaches require fit and corneal-health checks; all approaches need prescription and progression monitoring.

Does insurance cover myopia management?

Coverage varies and is often limited. See Well can review available benefits, but verification does not guarantee payment. The practice also explains private-pay choices without posting or promising a price online.

Build a Plan Around Your Child

If your child’s prescription is changing, request a myopia-management evaluation. Bring prior prescriptions and current glasses so Dr. Baik can evaluate the pattern rather than one number.

About the Author

Dr. Rawzi Baik is the owner and optometrist at See Well Eyecare, an independent Hyde Park practice serving Cincinnati. He earned his Doctor of Optometry degree from The Ohio State University and provides comprehensive, medical, contact-lens, dry-eye, pediatric and myopia-management care with clear explanations and individualized follow-up.

Primary keyword: myopia management options Cincinnati
Supporting keywords: Stellest vs MiSight, Ortho-K Cincinnati, low-dose atropine myopia, childhood myopia treatment, myopia control Hyde Park